≥65岁未接种肺炎球菌疫苗成人中PCV13序贯PPSV23的安全性与免疫原性:基于0.5年与1.0年间隔的加强效应比较
开放标签研究纳入≥65岁未接种肺炎球菌疫苗成人129例,比较PCV13后0.5年或1.0年序贯PPSV23与单剂PPSV23的免疫原性和安全性。1.0年间隔组PPSV23后1个月IgG和OPA的GMFR升高血清型数多于0.5年间隔组,两间隔组局部反应频率无显著差异。
要点
- 1.0年间隔组PPSV23后1个月IgG的GMFR在8个血清型中5个显著升高,0.5年间隔组仅2个显著升高。
- 1.0年间隔组OPA的GMFR在全部8个血清型显著升高,0.5年间隔组仅4个显著升高。
- 初种后2年,除血清型3外,各间隔组IgG或OPA的GMFR均高于单剂PPSV23组。
核心结论
- 在≥65岁未接种肺炎球菌疫苗成人中,PCV13序贯PPSV23以1.0年间隔给予时,PPSV23诱导的加强效应优于0.5年间隔。
- 两种间隔的安全性特征无差异。
研究设计与样本
- 开放标签研究,纳入≥65岁未接种肺炎球菌疫苗成人129例。
- 受试者接受0.5年间隔或1.0年间隔的PCV13序贯PPSV23,或单剂PPSV23。
- 在每次接种前、接种后1个月及2年内每0.5年评估免疫原性。
主要发现
- PPSV23后1个月,1.0年间隔组IgG的GMFR在8个血清型中5个显著升高,0.5年间隔组仅2个显著升高。
- PPSV23后1个月,1.0年间隔组OPA的GMFR在全部8个血清型显著升高,0.5年间隔组仅4个显著升高。
- 初种后2年,除血清型3外,各间隔组IgG或OPA的GMFR均高于单剂PPSV23组。
- 两种间隔组所有级别局部反应频率无显著差异。
关键数值与推荐
- 主要终点为PPSV23后1个月8个常见血清型IgG或OPA的几何平均倍数升高(GMFR)的增幅。
- 次要终点为单剂PPSV23的安全性特征。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: An open-label study was conducted to compare the safety and immunogenicity of a sequential administration of 13-valent pneumococcal conjugate vaccine (PCV13) followed by 23-valent pneumococcal polysaccharide vaccine (PPSV23) between an interval of 0.5 (0.5-y) and 1 year (1.0-y) in adults aged ≥ 65 years. METHODS: Pneumococcal vaccine-naïve adults aged ≥ 65 years (n = 129) received a sequential administration with an interval of 0.5-y or 1.0-y or received a single administration of PPSV23 (single PPSV23). We evaluated the immunogenicity before and 1 month after each vaccination and at 0.5-y intervals for 2 years. The primary endpoint was the increase in geometric mean fold rises (GMFRs) of immunoglobulin G (IgG) or opsonophagocytic activity (OPA) for eight common serotypes one month after one dose of PPSV23. The secondary endpoint was the safety profile for one dose of PPSV23. RESULTS: One month after administration of PPSV23, the GMFRs of IgG considerably increased for five of eight serotypes in the 1.0-y interval group, whereas the GMFRs of IgG considerably increased for two serotypes in the 0.5-y interval group. Furthermore, GMFRs of OPA markedly increased for all eight serotypes in the 1.0-y interval group, while GMFRs of OPA markedly increased for four serotypes in the 0.5-y interval group. At 2 years after initial vaccination, GMFRs of IgG or OPA were higher for all serotypes, except for serotype 3, than those in the single PPSV23 group irrespective of intervals. No significant difference was found in the frequencies of local reactions of all grades between the two intervals. CONCLUSIONS: The 1.0-y interval provided better booster effects induced by PPSV23 than those of the 0.5-y interval in a sequential administration in pneumococcal vaccine-naïve adults aged ≥ 65 years. No difference was found in the safety profile between both intervals.
引用
- Azuma M, Oishi K, Akeda Y, et al. Safety and immunogenicity of sequential administration of PCV13 followed by PPSV23 in pneumococcal vaccine-naïve adults aged ≥ 65 years: Comparison of booster effects based on intervals of 0.5 and 1.0 year. Vaccine. 2022. PMID: 36593171. doi:10.1016/j.vaccine.2022.12.060
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。